TABLE 5.
Summary of PM data for two-component mutantsa
| System (HK/RR) | Function(s) | No. of phenotypesb
|
New phenotype(s) or function(s) | |
|---|---|---|---|---|
| Gained | Lost | |||
| ArcA (RR) | Respiration control | 2 | 47 | Nonec |
| ArcB (hybrid) | Respiration control | 2 | 59 | Nonec |
| AtoS/AtoC | Acetoacetate metabolism | 1 | 5 | Glucuronamide use and NaCl sensitivity |
| BaeS/BaeR | Unknown | 0 | 4 | Sodium tungstate sensitivity |
| BarA (hybrid) | Hydrogen peroxide sensitivity | 2 | 0 | Melibiose metabolism |
| UvrY (RR) | Hydrogen peroxide sensitivity | 2 | 5 | Melibiose metabolism |
| CpxA/CpxR | Cell envelope stress | 0 | 23 | Ethylene glycol sensitivity |
| CusS/CusR | Response to copper | 0 | 1 | 1,10-Phenanthroline sensitivity |
| DcuS/DcuR | C4 dicarboxylate utilization | 0 | 9 | None |
| EnvZ/OmpR | Osmotic regulation | 12 | 8 | Increased use of carbohydrates, cephalosporin resistance |
| KdpD/KdpE | Potassium transport | 1 | 1 | Novobiocin resistance |
| NarP (RR) | Nitrate regulation | 0 | 1 | Chelator sensitivity |
| NtrB/NtrC | Nitrogen regulation | 2 | 23 | Aminoglycoside sensitivity |
| PhoQ/PhoP | Response to magnesium | 2 | 0 | Increased use of fructose and mannitol |
| PhoR/PhoB | Phosphate regulation | 0 | 8 | Noned |
| QseC/QseB | Quorum sensing | 0 | 5 | Metal sensitivity |
| RcsB (RR) | Capsule synthesis | 0 | 6 | NaCl and trimethoprim sensitivity |
| RcsC/YojN(Hpt)/RcsB | Capsule synthesis | 0 | 6 | NaCl and trimethoprim sensitivity |
| YojN(Hpt) | 0 | 6 | NaCl sensitivity | |
| RssB (RR) | σS Stability | 0 | 53 | Decreased use of C4 di- and monocarboxylates and amino acid N sources |
| RstB/RstA | Unknown | 0 | 3 | Ketoprofen, pridinol, and troleandomycin sensitivity |
| UhpB/UhpA | Hexose phosphate uptake | 0 | 2 | None |
a
The following 15 other two-component mutants did not have altered phenotypes: BasS/BasR, CheA (HK)/CheB (RR)/CheY (RR), DpiB/DpiA, CreC/CreB, EvgS/EvgA, FimZ (RR), ZraS/ZraR, NarX/NarL, NarQ (HK), TorS/TorR, YedV/YedW, YehU/YehT, YfhK (HK), YfhA (RR), and YpdA/YpdB.
b
Phenotypes gained means PM assays showing increased growth or respiration (positive values in Table 4). Phenotypes lost means PM assays showing decreased growth or respiration (negative values in Table 4).
c
The arcA and arcB mutants had many phenotypes that were attributed to membrane-associated functions, which may be considered new.
d
As mentioned in the text, two of the three phoBR mutants showed increased sensitivity to aminoglycoside.